Patents by Inventor Gary E. Schiltz

Gary E. Schiltz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200399241
    Abstract: Disclosed are indazole compounds and derivatives thereof for use as modulators of the activity of mitogen-activated protein kinase 4 (MEK4). The disclosed compounds include 3-Arylindazoles which may be formulated in pharmaceutical composition for treating cell proliferative diseases and disorders associated with MEK4 activity, including cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: December 24, 2020
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Karl A. Scheidt, Gary E. Schiltz, Matthew R. Clutter, Ada J. Kwong
  • Publication number: 20200390894
    Abstract: Disclosed are proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein. The disclosed PROTACs typically include a first targeting moiety that binds to c-MYC (Mc-MYC) which may be derived from a substituted heterocycle that binds to c-MYC such as a substituted pyrazole. The first targeting moiety typically is linked via a bond or a linker (L) to a second targeting moiety that binds to an E3 ubiquitin ligase (ME3). As such, the disclosed PROTACS may be described as having a formula Mc-MYC-L-ME3 or ME3-L-Mc-MYC.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Gary E. Schiltz, Atul Jain, Huiying Han, Sarki A. Abdulkadir
  • Publication number: 20200392116
    Abstract: Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.
    Type: Application
    Filed: June 17, 2020
    Publication date: December 17, 2020
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Gary E. SCHILTZ, Atul JAIN, Huiying HAN, Sarki A. ABDULKADIR
  • Patent number: 10851082
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: December 1, 2020
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Javier Izquierdo-Ferrer, Purav Vagadia, Matthew R. Clutter, Rama K. Mishra, Leonidas C. Platanias
  • Patent number: 10640502
    Abstract: Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 5, 2020
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin Richard Smith, Gary E. Schiltz
  • Publication number: 20200039941
    Abstract: Provided herein are small molecule modulators of CXCR4 activity (e.g., agonists, antagonists, inverse agonists, partial agonists), and methods of use thereof (e.g., for the treatment of disease).
    Type: Application
    Filed: October 8, 2019
    Publication date: February 6, 2020
    Inventors: Gary E. Schiltz, Richard J. Miller, Rama K. Mishra
  • Patent number: 10435375
    Abstract: Provided herein are small molecule modulators of CXCR4 activity (e.g., agonists, antagonists, inverse agonists, partial agonists), and methods of use thereof (e.g., for the treatment of disease).
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 8, 2019
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Richard J. Miller, Rama K. Mishra
  • Publication number: 20190276458
    Abstract: Disclosed are compounds, pharmaceutical compositions, and methods of treatment. The disclosed compounds are based on fused 1,4-diazepine and pyrrolidinedione scaffolds. The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with cell proliferation such as cancer.
    Type: Application
    Filed: March 7, 2019
    Publication date: September 12, 2019
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Karl A. Scheidt
  • Publication number: 20190062281
    Abstract: Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.
    Type: Application
    Filed: August 31, 2018
    Publication date: February 28, 2019
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Rama K. Mishra, Huiying Han, Sarki A. Abdulkadir, Javier Izquierdo-Ferrer, Atul D. Jain
  • Patent number: 10093668
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 9, 2018
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Rama K. Mishra, Leonidas C. Platanias, Javier Izquierdo-Ferrer
  • Publication number: 20180244654
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Javier Izquierdo-Ferrer, Purav Vagadia, Matthew R. Clutter, Rama K. Mishra, Leonidas C. Platanias
  • Publication number: 20180155295
    Abstract: Provided herein are small molecule modulators of CXCR4 activity (e.g., agonists, antagonists, inverse agonists, partial agonists), and methods of use thereof (e.g., for the treatment of disease).
    Type: Application
    Filed: May 5, 2016
    Publication date: June 7, 2018
    Inventors: Gary E. Schiltz, Richard J. Miller, Rama K. Mishra
  • Patent number: 9981968
    Abstract: Disclosed are substituted pyrrolo[2,3-d]pyrimidine compounds.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: May 29, 2018
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Karl A. Scheidt, Steven T. Rosen, Nancy L. Krett
  • Publication number: 20170253581
    Abstract: Disclosed are substituted heterocycles compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 7, 2017
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Rama K. Mishra, Huiying Han, Sarki A. Abdulkadir
  • Patent number: 9688637
    Abstract: Disclosed are novel benzamide compounds and the uses thereof for treating diseases and disorders in a patient in need thereof by increasing cellular levels of A3G and/or other members of the A3 family of proteins in the patient. The disclosed compounds include 3-benzamide compounds that may be administered treat an HIV-1 infection or cancer in a patient.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: June 27, 2017
    Assignee: Northwestern Universtiy
    Inventors: Gary E. Schiltz, Chisu Song, Richard T. D'Aquila, Meejeon Roh
  • Patent number: 9669014
    Abstract: Disclosed are new small molecules and the uses thereof for inhibiting superoxide dismutase (SOD) expression. Also disclosed are pharmaceutical compositions comprising the small molecule inhibitors which may be administered in methods of treating diseases or disorders associated with elevated SOD expression or activity, including neurological diseases and disorders such as amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: June 6, 2017
    Assignee: Northwestern University
    Inventors: Teepu Siddique, Thomas J. Lukas, Hasan Arrat, Gary E. Schiltz
  • Publication number: 20170121326
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Application
    Filed: October 28, 2016
    Publication date: May 4, 2017
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Rama K. Mishra, Leonidas C. Platanias, Javier Izquierdo-Ferrer
  • Publication number: 20160214969
    Abstract: Disclosed are new small molecules and the uses thereof for inhibiting superoxide dismutase (SOD) expression. Also disclosed are pharmaceutical compositions comprising the small molecule inhibitors which may be administered in methods of treating diseases or disorders associated with elevated SOD expression or activity, including neurological diseases and disorders such as amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: March 29, 2016
    Publication date: July 28, 2016
    Applicant: Northwestern University
    Inventors: Teepu Siddique, Thomas J. Lukas, Hasan Arrat, Gary E. Schiltz
  • Publication number: 20160052870
    Abstract: Disclosed are novel benzamide compounds and the uses thereof for treating diseases and disorders in a patient in need thereof by increasing cellular levels of A3G and/or other members of the A3 family of proteins in the patient. The disclosed compounds include 3-benzamide compounds that may be administered to treat an HIV-1 infection or cancer in a patient.
    Type: Application
    Filed: August 21, 2015
    Publication date: February 25, 2016
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Chisu Song, Richard T. D'Aquila, Meejeon Roh
  • Publication number: 20160002252
    Abstract: Disclosed are substituted pyrrolo[2,3-d]pyrimidine compounds. The disclosed compounds are shown to be useful in inhibiting the growth of cancer cell lines and treating cancer and cell proliferative disorders.
    Type: Application
    Filed: September 15, 2015
    Publication date: January 7, 2016
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Karl A. Scheidt, Steven T. Rosen, Nancy L. Krett